Preview

Онкоурология

Расширенный поиск

Клиническое значение молекулярно-генетических изменений в клетках уротелия при раке мочевого пузыря

https://doi.org/10.17650/1726-9776-2006-2-3-54-58

Полный текст:

Об авторах

С. В. Башкатов
ГУ МРНЦ РАМН, Обнинск
Россия


М. В. Немцова
НИИ молекулярной медицины ММА им. И.М. Сеченова; Медико-генетический научный центр РАМН
Россия


О. Б. Карякин
ГУ МРНЦ РАМН, Обнинск
Россия


Список литературы

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М.; 2005.

2. Millan-Rodrigez F.,Chechile-Toniolo R. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163:68–7.

3. Vet J.A., Bringuier P.P., Schaafsma H.E. et al. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 1995;73(6):837–43.

4. Лопаткин Н.А., Мартов Б.М. и соавт. Современные подходы в лечении поверхностного рака мочевого пузыря. В кн.: Рак мочевого пузыря. Материалы 4-й Всероссийской научной конференции с участием стран СНГ. М.; 2002. с. 50–1.

5. Allard P., Bernard P., Fradet Y. еt al. The early clinical course of primary Ta and T1 bladder cancer. Europ Urol 1998;8(1):692–8.

6. Fleming F. et. al. Urinary bladder. In: Cancer staging manual. Philadelphia, Lippincot-Raven;1997. p. 241–24.

7. Malmstrom P., BuschC., Norlen B.J. Recurrences, progression and survial in bladder cancer. Scand J Urol Nephrol 1987;21(2):185.

8. Kurt K. et al. The nature history and prognosis of tread superficial bladder cancer. EORTC GU Group. Prog Clin Biol Res 1992;378:1.

9. Holmang S., Hedelin H., Anderstrom C., Johansson S.L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of bladder followed for at least 20 years. J Urol 1995;153(16);1823–6; discussion 1826–7.

10. Witjes J.A., Kiemeney L.A., Schaafsma H.E., Debruyn F.M. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch Sought East cooperative Urological Group. Br J Urol 1994; 73(2): 172–6.

11. Placer J. et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42:547–52.

12. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nature Med 2004; 10: 789–99.

13. Spruk C.H. 3 rd., Ohneseit P.F., Gonzalez-Zulueta M. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54(3):784–8.

14. Dalbagni S., Presti J.C. Jr., Reuter V.E. et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diags Mol Pathol 1993; 2(1):4–13.

15. von Knobloch R. et al. Allelic imbalance at chromosomes 5q,8p and 17p as progression markers for bladder cancer. Aktuel Urol 2000, 31: 83–6.

16. Vogelstein B., Kinzler K.W. The genetic basis of human cancerl. McGraw-Hill Medical Pablishing Division; 2002. p. 697–702.

17. Cairns P., Polascik T.J., Eby Y. et al. Frequence of homozygous deletions at p16/CDKN2 in primary human tumors. Nat Genet 1995;11(2):210–2.

18. Prat E., Bernues M., Caballin M.R. et al. Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 2001; 57(5):986–92.

19. van Rhijn B.W. Lurkin I., Radvanyi F. et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61(14),1265–8.

20. Billerey C., Chopin D., Aubriot-Lorton M.H. et al. Frequent FGFR3 mutation in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158(6):1955–9.

21. Esrig D., Elmajian D., Groshen S. et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331(19):1259–64.

22. Esrig D., Spruck C.H. 3 rd, Nichols P.W. et al. p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143(5):1389–97.

23. Cordon-Cardo C., Dalbagni G., Saez G.T. et al. P53 mutation in human bladder cancer: Genotypic vs phenotypic patterns. Int J Cancer 1994;56(3):347–53.

24. Sarkis A.S., Dalbagni G., Cordon-Cardo C. et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993;85(1): 53–9.

25. Bakkar A. Wallerand H., Radvanyi F. et al. FGFR3 and TP53 gene mutation two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63 (23):8108–12.

26. Hartmann A., Schlake G., Zaak D. et al. Occurrence of chromosome 9 and p53 alteration in multifocal displasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809–18.

27. Belinsky S.A., Nikula K.J., Palmisano W.A. et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998,95(20):11891–6.

28. Obermann E.C., Meyer S., Hellge D. et al Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol Rep 2004; 11(4): 745–51.

29. Perl A.K., Wilgenbus P., Dahl U. et al. A casual role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392(6672):190–3.

30. Shariat S.F., Matsumoto K., Casella R. et al. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 2005;48(1):69–76.

31. Michael W.Y. et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8:464–70.

32. Domingues G. et al. p14ARF promoter hypermethylation in plasma DNA as indicator of disease reccurence in bladder cancer patients. Clin Cancer Res 2002; 8:980–5.


Для цитирования:


Башкатов С.В., Немцова М.В., Карякин О.Б. Клиническое значение молекулярно-генетических изменений в клетках уротелия при раке мочевого пузыря. Онкоурология. 2006;2(3):54-58. https://doi.org/10.17650/1726-9776-2006-2-3-54-58

For citation:


Bashkatov S.V., Nemtsova M.V., Karyakin O.B. Clinical value of chromosomal genetic changes in urothelial cells in urinary bladder cancer. Cancer Urology. 2006;2(3):54-58. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-3-54-58

Просмотров: 60


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X